SpyGlass Pharma Makes US Market Debut with Shares Soaring Over 43%

Stock News

6 hours ago

On Friday, SpyGlass Pharma Inc (SGP.US) commenced trading on the US stock market. The stock opened sharply higher, surging more than 43% to $23 per share, compared to its IPO price of $16. SpyGlass Pharma is a late-stage clinical biotechnology company focused on developing sustained drug delivery systems for chronic ocular diseases. The company aims to enhance patient vision and quality of life through longer-acting and more sustainable treatment options. Its core research and development product includes a system that integrates a drug delivery insert with an intraocular lens, designed to treat chronic eye conditions such as open-angle glaucoma or ocular hypertension. This type of therapy seeks to improve efficacy and patient adherence, offering potential advantages over traditional daily eye drop regimens.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1152444720"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152444720\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152444720?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-07 01:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152444720","market":"fut","top_or_hot":-1,"title":"SpyGlass Pharma Makes US Market Debut with Shares Soaring Over 43%","media":"Stock News","content":"<p>On Friday, SpyGlass Pharma Inc (SGP.US) commenced trading on the US stock market. The stock opened sharply higher, surging more than 43% to $23 per share, compared to its IPO price of $16. SpyGlass Pharma is a late-stage clinical biotechnology company focused on developing sustained drug delivery systems for chronic ocular diseases. The company aims to enhance patient vision and quality of life through longer-acting and more sustainable treatment options. Its core research and development product includes a system that integrates a drug delivery insert with an intraocular lens, designed to treat chronic eye conditions such as open-angle glaucoma or ocular hypertension. This type of therapy seeks to improve efficacy and patient adherence, offering potential advantages over traditional daily eye drop regimens.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SpyGlass Pharma Makes US Market Debut with Shares Soaring Over 43%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpyGlass Pharma Makes US Market Debut with Shares Soaring Over 43%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-07 01:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On Friday, SpyGlass Pharma Inc (SGP.US) commenced trading on the US stock market. The stock opened sharply higher, surging more than 43% to $23 per share, compared to its IPO price of $16. SpyGlass Pharma is a late-stage clinical biotechnology company focused on developing sustained drug delivery systems for chronic ocular diseases. The company aims to enhance patient vision and quality of life through longer-acting and more sustainable treatment options. Its core research and development product includes a system that integrates a drug delivery insert with an intraocular lens, designed to treat chronic eye conditions such as open-angle glaucoma or ocular hypertension. This type of therapy seeks to improve efficacy and patient adherence, offering potential advantages over traditional daily eye drop regimens.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"","article_id":"1152444720","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152444720","pubTimestamp":1770398810,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"On Friday, SpyGlass Pharma Inc (SGP.US) commenced trading on the US stock market. The stock opened sharply higher, surging more than 43% to $23 per share, compared to its IPO price of $16. SpyGlass...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","SRTY":"罗素2000指数三倍做空ETF-ProShares","UWM":"罗素2000指数ETF两倍做多","IWN":"罗素2000价值股指数ETF-iShares","BK4581":"高盛持仓","BK4534":"瑞士信贷持仓","BK4588":"碎股","TZA":"罗素2000指数三倍做空ETF","IWO":"罗素2000成长股指数ETF","TNA":"罗素2000指数三倍做多ETF-Direxion","RWM":"罗素2000指数反向ETF","SGP":"SpyGlass Pharma Inc","BK4550":"红杉资本持仓","BK4585":"ETF&股票定投概念","TWM":"罗素2000指数两倍做空ETF"},"translate_title":"SpyGlass Pharma在美国上市，股价飙升超过43%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNA":1,"SGP":1,"TZA":1,"TWM":1,"MNQmain":1,"RWM":1,"SRTY":1,"IWO":1,"UWM":1,"IWN":1},"content_text":"On Friday, SpyGlass Pharma Inc (SGP.US) commenced trading on the US stock market. The stock opened sharply higher, surging more than 43% to $23 per share, compared to its IPO price of $16. SpyGlass Pharma is a late-stage clinical biotechnology company focused on developing sustained drug delivery systems for chronic ocular diseases. The company aims to enhance patient vision and quality of life through longer-acting and more sustainable treatment options. Its core research and development product includes a system that integrates a drug delivery insert with an intraocular lens, designed to treat chronic eye conditions such as open-angle glaucoma or ocular hypertension. This type of therapy seeks to improve efficacy and patient adherence, offering potential advantages over traditional daily eye drop regimens.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}